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Summary
 
It is currently believed that latently infected, resting B lymphocytes are central to gammaher-
pesvirus persistence, whereas mucosal epithelial cells are considered nonessential. We have re-
addressed the question of nonlymphoid persistence using murine gammaherpesvirus 68 (MHV-
68). To dissect lymphoid from nonlymphoid persistence, we used
 
 
 
m
 
MT transgenic mice that
are defective in B cells. MHV-68 DNA persisted in the lungs of intact and B cell–deficient
mice. Both episomal and linear forms of the virus genome were present in lungs, implying the
presence of both latency and productive replication. In situ hybridization for virus tRNA tran-
scripts revealed latent MHV-68 in pulmonary epithelial cells. Infectious virus was recovered
from the lungs of 
 
m
 
MT mice after T cell depletion, showing that the persisting virus DNA was
reactivatable. Finally, using adoptive transfer of B cells into B cell–deficient mice, it was shown
that virus persisting in lungs seeded splenic B cells, and virus resident in the spleen seeded the
lungs. These results show that mucosal epithelia can act as a nonlymphoid reservoir for gamma-
herpesvirus persistence, and that there is a two-way movement of virus between lymphoid and
nonlymphoid compartments during persistence.
Key words: gammaherpesvirus • latency • Epstein-Barr virus • epithelia • lungs
 
G
 
ammaherpesviruses have clinical relevance in both the
medical and veterinary fields. In humans, EBV is asso-
ciated with infectious mononucleosis, B lymphomas, and
nasopharyngeal carcinoma (1). Likewise, the Kaposi’s sar-
coma–associated herpesvirus (KSHV)
 
1
 
 also called human
herpesvirus type 8, is associated with B lymphomas as well
as the lesion from whence its name is derived (2). In the
veterinary field, there is a group of closely related viruses,
including ovine herpesvirus type 2 and alcelaphine herpes-
virus type 1, which are associated with a fatal lymphoprolif-
erative syndrome in domestic ruminants termed malignant
catarrhal fever (3).
All gammaherpesviruses are characterized by their ability
to become latent in lymphoid cells. These viruses also in-
fect epithelial cells, especially in the respiratory tract, from
which they spread from host to host (1). To date, the mode
of gammaherpesvirus persistence in the host has been ad-
dressed only with EBV. Only productive, not latent, infec-
tion has been described at mucosal sites in epithelia, and as
such, these sites are considered nonessential to virus persis-
tence (4–6). Indeed, based on evidence currently available,
a pool of latently infected, resting B lymphocytes are the
central and essential feature of EBV persistence, and pha-
ryngeal epithelial cells are occasionally reinfected from
these cells (6–10). However, investigation of the pathogen-
esis of most gammaherpesviruses, in particular those infect-
ing humans, is difficult. Therefore, we are readdressing the
question of alterative sites of persistence and latency using
murine gammaherpesviruses 68 (MHV-68).
MHV-68 will infect laboratory mice via intranasal inoc-
ulation, after which it establishes a productive infection in
alveolar epithelial cells (11). The virus then spreads to the
spleen, where a latent infection is established in B lympho-
cytes (12). Acute virus replication in the lung resolves after
7–10 d postinfection (p.i.), beyond which time no evi-
dence of infection can be found in this organ by biological
methods, i.e., direct plaque assay or reactivation assays. In
contrast, latent virus can be reactivated from splenic B cells
throughout the lifetime of the animal. It was reasoned that,
like EBV, the B lymphoid compartment was the major site
of MHV-68 persistence and latency (12). However, our re-
cent work with 
 
m
 
MT mice, which are transgenically defi-
cient in mature B cells, has cast doubt on this hypothesis
(13). Infection of the lungs of these mice by MHV-68 fol-
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lowed a normal course, except that clearance of infectious
virus was delayed from 10–17 d p.i. We could find no evi-
dence of splenic or hematogenous infection or infection of
other organs either by reactivation assay or by using a sensi-
tive nested PCR assay. In contrast, using the same PCR as-
say, we were able to show long-term persistence of MHV-68
DNA in lungs. This showed that although the B cell is
clearly a major site of latency and persistence, it is not es-
sential for the persistence of the virus, and that this can oc-
cur at mucosal sites, in this case the lungs. The aim of this
work was to investigate further the long-term persistence
of MHV-68 in the lungs of infected mice, and to investi-
gate the trafficking of virus during persistence between B
cells in the spleen and epithelial cells in the lung.
 
Materials and Methods
 
Cell Lines and Virus.
 
MHV-68 strain g2.4 was propagated
and quantified by plaque assay using BHK-21 cells as described
previously (11). The B lymphocyte tumor cell lines S11 (MHV-
68–positive) and S31 (MHV-68–negative) were derived in this
laboratory, and were grown as described by Usherwood et al. (14).
 
Mice.
 
The mice used in this study were 
 
m
 
MT/
 
m
 
MT (15) on
a C57/BL6 background. They have a targeted lesion in the 
 
m
 
 im-
munoglobulin chain resulting in the failure to express IgM; con-
sequently, B cell development is arrested at the pre–B cell stage.
A colony was established from these mice in the Department of
Veterinary Pathology, University of Edinburgh. C57/BL6 mice
were obtained from Bantin and Kingman Ltd. (Hull, UK). Male
and female mice were infected at 4–11 wk of age intranasally
with 4 
 
3
 
 10
 
5
 
 PFU MHV-68 under halothane anesthesia.
 
DNA PCR Analysis.
 
MHV-68 DNA was extracted from cells
and tissue using Qiamp tissue kits (QIAGEN Inc., Chatsworth, CA).
Accurate DNA quantitation was performed using a DNA fluorome-
ter (DyNA Quant 200; Pharmacia Biotech AB, Uppsala, Sweden).
Nested PCR amplification was performed on 100 ng of high mo-
lecular weight DNA using primers specific for the gp150 gene as
described previously (13). The primer pair PAG1 plus PAG2 (ex-
ternal) was used for an initial 40 cycles, and the primer pair PAG11
and PAG12 was used for a subsequent 25 cycles on 10 
 
m
 
l of product
from the first amplification. Products were analyzed on 2% aga-
rose gels containing ethidium bromide.
Using known amounts of cloned template, it was determined
that the process could detect one copy of virus genome in 100 ng
high molecular weight DNA.
 
Quantitative Competitive PCR.
 
This was carried out essen-
tially as described by Gilliland et al. (16) and Siebert and Larrick
(17). The quantitative competitive (QC) PCR assay was based on
the gp150-specific assay described above. The template for the
gp150-specific PCR using primers PAG1 and PAG2 does not
contain a site for the restriction enzyme BamHI. A mutant com-
petitor template containing an internal BamHI restriction endo-
nuclease site for use in QC-PCR was made. Two separate PCRs
were performed using DNA containing the gp150 gene as tem-
plate. The first used the external primer PAG1 (sense; see above)
along with the primer MUT1, 5
 
9
 
-CAG GAA GAG GAT CCA
ACT ATG ACT C (antisense), which is specific for a sequence
 
z
 
200 bp downstream in the gp150 gene but with the sequence
mutated into a BamHI site. The second used the primer MUT2,
which is the reverse complement of MUT1, and the external
primer PAG2 (antisense). Two reaction products of 
 
z
 
200 and
300 bp in length were generated from these PCRs, representing
the upstream and downstream portions of the gp150 template.
The 3
 
9
 
 25 bp of the product of PAG1 and MUT1 overlapped with
the 5
 
9
 
 25 bp of the product of MUT2 and PAG2. Thus, when
portions (10 
 
m
 
l) of the products were mixed together with prim-
ers PAG1 and PAG2 and amplified by PCR, this resulted in the
generation of a 501-bp mutant gp150 template containing an in-
ternal BamHI site. When cut with BamHI, this template formed
fragments of 
 
z
 
200 and 300 bp in size. This mutant competitor
template was inserted using standard molecular cloning tech-
niques into the vector pKS (
 
2
 
) (Stratagene Inc., La Jolla, CA).
Accurate quantification of the copy number of MHV-68 DNA
present in samples was performed on 100 ng high molecular
weight DNA. A series of PCRs was performed on each sample
using primers PAG1 and PAG2, each containing the same
amount of high molecular weight DNA but spiked with a dilu-
tion series of defined quantities of mutant competitor template.
Nested PCR was then performed using primers PAG11 and
PAG12 as before, except that PAG12 had been labeled with
IRD-41. Reaction products were cut with BamHI, and the
amounts of labeled wild-type (501 bp) and competitor (300 bp)
product were assessed using a sequencing machine (LI-COR
Inc., Lincoln, NE) which detects IRD-41–labeled DNA. A stan-
dard curve was constructed using cloned wild-type DNA, and re-
lating log([competitor product]/[wild-type product]) to the log
[competitor]. This was found to be a straight line with a slope of
one. The exact amount of DNA in each sample was then deter-
mined by replacing cloned wild-type DNA with high molecular
weight test DNA, and calculating the point at which [competitor
product] is equal to [wild-type product] or log([competitor prod-
uct]/[wild-type product]) is equal to zero.
 
In Situ–Lysis Gardella Gels and PCR.
 
Gardella gel electrophore-
sis with PCR analysis was performed in a horizontal format as de-
scribed previously (7) with the following modification. Gel slices
were melted at 65
 
8
 
C, and 5 
 
m
 
l was analyzed directly by PCR for
MHV-68. A single round (nonnested) PCR for MHV-68 gp150
was used with primers PAG1 and PAG2 (see above) for 30–40
cycles.
 
Dissociation of Lungs to a Single Cell Suspension.
 
Before removal,
lungs were perfused through the right ventricle of the heart with
30 ml PBS. Lungs were removed and placed in ice-cold medium.
Larger airways were removed along with lung-associated lym-
phoid and connective tissue. The remaining tissue was then cut
into pieces of 
 
z
 
1–2 mm
 
3
 
. Diced lung was then incubated with a
solution of 150 U/ml collagenase/dispase (Sigma Chemical Co.,
St. Louis, MO) and 50 U/ml DNase I (Sigma Chemical Co.) in
RPMI 1640 medium containing 10% FCS for 2 h at 37
 
8
 
C and
then dissociated by passing through a 23-gauge needle. The sus-
pension was then washed twice with 10 ml medium and evalu-
ated by trypan blue staining. Between 2 and 5 
 
3
 
 10
 
7
 
 viable cells
were obtained per mouse.
 
In Vivo Depletion of T Cells.
 
T cell subsets were depleted us-
ing the rat mAbs YTS 191.1 (anti-CD4) and YTS 169.4 (anti-
CD8). Mice were injected intravenously in the tail with 0.1 ml of
antibody at 10 mg/ml and again 2 d later. Subsequently, mice
were injected with the same dose intraperitoneally at 7 and 11 d
after the original injection.
 
Cytofluorometry.
 
Cells were stained with mAbs and analyzed
using a FACScan
 
Ò
 
 (Becton Dickinson, San Jose, CA) as described
previously (13). Anti-CD4 and anti-CD8 antibodies were from
the hybridomas YTS 191.1 and YTS 169.4, and anti-B220
(CD45R) was purchased from PharMingen (San Diego, CA).
 
Adoptive Transfer of T-depleted Splenocytes.
 
Splenocytes were first 
1943
 
Stewart et al.
removed from spleens by teasing, and then red cells were lysed by
water. Cells were then incubated with anti-CD4 (YTS 191.1)
and anti-CD8 (YTS 169.4) both at 100 
 
m
 
g/ml along with a 1:4
dilution of rabbit complement (Lowtox-H; Cedarlane Labs. Ltd.,
Hornby, Ontario, Canada). After incubation for 1 h at 37
 
8
 
C, the
cells were washed, and 5 
 
3
 
 10
 
7
 
 cells in 200 
 
m
 
l PBS were given
intraperitoneally to each mouse.
 
In Situ Hybridization.
 
Radioactive and nonradioactive in situ
hybridizations on formalin-fixed, paraffin-embedded sections
were carried out essentially as described previously (18). Sense
and antisense labeled transcripts to the MHV-68 tRNA mole-
cules 1–4 were made from the plasmid pEH 1.4 (a gift of Dr. S.
Efstathiou, University of Cambridge, Cambridge, UK [19]) using
either T3 or T7 polymerases, respectively. Likewise, labeled tran-
scripts to the MHV-68 thymidine kinase gene were made using
the gene contained in pKS (
 
2
 
) (Stratagene Inc.) (20). Detection
of tRNAs and cytokeratin on the same section was performed as
follows. Sections were pretreated for in situ hybridization, which
included microwave treatment in citrate buffer as described by Si-
bony et al. (21). Hybridization was performed with a digoxigenin-
labeled tRNA probe, and slides were developed using 5-bromo-
4-chloro-3-indolyl phosphate/nitro blue tetrazolium (BCIP/NBT)
substrate (Sigma Chemical Co.) as described previously (18). Sec-
tions were then reacted with anticytokeratin/HRP (MNF116-
EPOS, U7022; Dakopatts A/S, Copenhagen, Denmark) according
to the manufacturer’s instructions, and ultimately developed using
3,3
 
9
 
-diaminobenzidine tetrahydrochloride (DAB) substrate (Sigma
Chemical Co.).
 
Results
 
MHV-68 Persists in the Lungs of Intact Mice.
 
Our previ-
ous results using PCR analysis had shown that MHV-68
could persist in the lungs of B cell–deficient 
 
m
 
MT mice after
infection by the intranasal route in the absence of infection
in the spleen or other organs (13). To confirm that persis-
tence in lungs was not merely an anomaly of 
 
m
 
MT mice,
we analyzed intact mice that had been infected 12 mo pre-
viously with MHV-68. We wanted to distinguish positive
signals derived from MHV-68 in B lymphocytes merely
trafficking through the lungs in the blood supply from
those derived from lung tissue. Therefore, we perfused
lungs extensively with PBS before removal and extracted
high molecular weight DNA from the blood, bone mar-
row, and liver in addition to the lungs and spleen of five
mice. The DNA was then analyzed for the presence of
MHV-68 genome by nested PCR (13). This assay was specific
for the MHV-68 pg150 gene and was sensitive to 1 ge-
nome copy per 100 ng DNA. The results are shown in Fig.
1. As expected, MHV-68 DNA was found in the lungs and
spleen of all five mice. However, none of the mice had
MHV-68 in their liver or kidney. Two mice (2 and 3) had
evidence of MHV-68 DNA in their blood and bone mar-
row. Therefore, in the case of mice 2 and 3, the positive
signal in lung tissue could have been due to MHV-68 traf-
ficking in the blood. This is unlikely to be the case in the
other three mice, since they had no detectable MHV-68
DNA either in their blood or in the liver and kidney. This
data shows that MHV-68 persists in the lungs of intact
mice as well as the spleen, and shows that our original ob-
servations with 
 
m
 
MT mice were not due to an artifact of a
B cell–deficient system.
To ascertain whether there was any relationship between
the levels of MHV-68 DNA in the lung, spleen, and bone
marrow, we measured the exact amount of virus DNA in
each organ by QC-PCR. This assay was developed as de-
scribed in Materials and Methods, and was sensitive to 1 copy
of genome per 100 ng DNA. The results of performing this
assay on the same five DNA samples as used in Fig. 1 are
shown in Fig. 2. The level of MHV-68 DNA present in
the lungs showed the greatest variability, from 1 to 1,000
copies/100 ng, whereas the levels in the spleen were more
consistent (12–300 copies/100 ng). The level of virus
DNA in the bone marrow, where detected, was much
lower (1–10 copies/100 ng). There was no direct relation-
ship between levels of virus DNA in the lungs and spleen.
In two mice, there was a higher level in spleen than lung,
the converse was true in another two mice, and one mouse
had equal levels in both. In contrast, the level of virus
DNA in the spleen bore a direct relationship to the level in
the bone marrow. This suggests that in intact C57/BL6
mice, both the lungs and the spleen may be independent
sites of MHV-68 persistence. The presence of and levels of
virus in the bone marrow appear to be directly related to
the amount of virus in the spleen, suggesting that the bone
marrow may not be an independent site of virus persistence
Figure 1. Detection of MHV-68 in C57/BL6 mice by PCR. DNA
was extracted from organs of five C57/BL6 mice which had been in-
fected intranasally with MHV-68 for 12 mo and analyzed for the presence
of MHV-68 DNA by nested PCR specific for the gp150 gene. Products
were analyzed on 2% agarose gels containing ethidium bromide and visu-
alized using a UV transilluminator. Images are shown with the colors re-
versed for clarity. Molecular weight determinations were made relative to
a 1-kb DNA ladder (Mr), and the size of the pertinent bands in bp are
shown at the left. In all panels, DNA from the MHV-68–positive tumor
cell line S11 was used as a positive control (1VE), and produced the ex-
pected product of 368 bp. DNA from the MHV-68–negative tumor cell
line S31 (2VE) was used along with deionized water (H2O) as a negative
control. (A) The results of analysis of lungs (LUNG 1–5), spleens (SPL 1–5),
and bone marrows (BM 1–5) of all five mice. (B) Analysis of blood
(BLOOD 1–5) of all five mice. (C) Analysis of livers (LIV 1–5) and kid-
neys (KID 1–5) of all five mice. 
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but is dependent on trafficking cells in the blood and/or
seeding from the spleen. This may also suggest a more cen-
tral role for splenic persistence in intact mice with regard to
seeding of other organs.
 
Both Episomal and Linear Forms of MHV-68 DNA Are
Present during Persistence in Lungs.
 
The state of MHV-68
in lungs during persistence was determined by molecular
means using Gardella gel analysis. This technique is able to
distinguish linear from episomal genomes. Using this tech-
nique, it has been shown that latently infected cells contain
genomes that are in a covalently closed, circular (episomal)
conformation. In contrast, although many forms of the ge-
nome may be present in productively replicating cells,
Gardella gel analysis of such cells reveals only genomes that
are in a linear conformation (7, 14, 22). In control experi-
ments, we performed Southern analysis of a Gardella gel as
described previously (14). We used the S11 B lymphocyte
line, which is known to contain both latent and productive
forms of MHV-68. Approximately 5% of these cells are
known to be undergoing productive replication at any one
time while the remainder are latent (14). We also used
acutely infected mouse epithelial cells (C127). The results
are shown in Fig. 3. 
 
A
 
 clearly shows the resolution of linear
and circular forms of the MHV-68 genome in S11 cells,
whereas 
 
B
 
 shows that only the linear form of the genome
was present in acutely infected epithelial cells.
To obtain the required sensitivity to be able to detect
MHV-68 during persistence in lungs, we needed to use a
PCR-based modification of the Gardella gel technique,
which has been used successfully to detect latent EBV and
KSHV genomes in vivo (7, 22). Instead of analyzing the
Gardella gel by Southern blotting, after electrophoresis in-
dividual lanes of the gel were excised and cut sequentially
into slices. Each slice was then analyzed for the presence of
MHV-68 DNA by PCR. Therefore, each lane of the PCR
gel represents one sequential slice of the Gardella gel lane.
Again in control experiments, we used S11 cells. This line
was used either untreated or after treatment for 14 d with
the antiviral drug 2
 
9
 
-deoxy-5-ethyl-
 
b
 
-4
 
9
 
-thiouridine (4
 
9
 
-
S-EtdU) (23). This drug is thought to act like Acyclovir, is
phosphorylated by the viral thymidine kinase, and causes
inhibition of DNA synthesis by chain termination. By this
means, it is known to inhibit productive MHV-68 replica-
tion but does not affect latency. The results are shown be-
low those of conventional Southern blots in Fig. 3. 
 
C
 
 shows
analysis of untreated S11 cells. As in 
 
A
 
, the resolution of
both episomal and linear forms of the genome in this panel can
be seen clearly. After treatment of S11 cells with 4
 
9
 
-S-EtdU
(
 
D
 
), the linear form of the genome was absent, representing
the predicted blocking of DNA replication and clearance
of linear DNA from the cells by the drug. Therefore, the
Gardella-PCR system was able to distinguish episomal
from linear genomes in control cells.
We next analyzed cells derived from mouse lungs. We
used primarily 
 
m
 
MT mice in these experiments, since lungs
are a site of persistence in these mice, and there is no de-
tectable hematogenous source of virus. Intact C57/BL6
mice were used as comparison. Lungs were taken from
mice during the persistent phase of infection: 2 mo p.i. in
the case of 
 
m
 
MT mice, and 7 mo p.i. in the case of C57/
BL6 mice. Selected mice were treated with the herpesvirus
DNA replication inhibitor 4
 
9
 
-S-EtdU. Treated mice re-
ceived 1 mg/mouse/d of drug in the drinking water con-
tinuously for 28 d before sampling. This concentration of
Figure 2. Determination of
MHV-68 DNA load in organs
by QC-PCR. The precise num-
ber of copies of MHV-68 DNA
present in the lung, spleen, and
bone marrow (BM) in the same
samples as in Fig. 1 was deter-
mined by QC-PCR. The results
are presented on a scatter chart as
the number of copies per 100 ng
high molecular weight DNA for
each organ in each mouse.
Mouse 1 (r); mouse 2 (j);
mouse 3 (m); mouse 4 (X); and
mouse 5 (d).
Figure 3. Analysis of MHV-68 DNA conformation in control cells by
Gardella gel analysis. DNA in intact cells was fractionated using a Gardella
(in situ–lysis) gel. A and B show Southern blot analysis of a Gardella gel.
The gel is shown sideways for comparison with C and D, and the top of
the gel is indicated (TOP). A shows the results of using the MHV-
68–positive B cell line S11, which is known to contain both episomal and
linear DNA. B shows the results of using C127 (murine epithelial cells),
which had been acutely infected 24 h previously with 10 PFU/cell
MHV-68.  C and D show the results of slicing the Gardella gel and analyz-
ing each slice for the presence of MHV-68 DNA by PCR. Therefore,
each panel represents one lane of a Gardella gel, and the top is shown next
to the first of the sequential slices. PCR products were analyzed on 2%
agarose gels containing ethidium bromide and visualized using a UV
transilluminator. Images are shown with the colors reversed for clarity.
DNA from the MHV-68–positive tumor cell line S11 was used as a posi-
tive control (1), and produced the expected product of 368 bp. DNA
from the MHV-68–negative tumor cell line S31 (2) was used as a nega-
tive control. C shows the results of using S11 cells as for A, and D shows
the results of using S11 cells after treatment with the virus DNA replica-
tion inhibitor 49-S-EtdU for 14 d. The positions of circular and linear
MHV-68 DNA are shown (top). 
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drug is known to completely inhibit productive MHV-68
DNA synthesis and replication in vivo. Lungs of both
 
m
 
MT and C57/BL6 mice were perfused through the right
ventricle to minimize contamination by lymphocytes in the
blood supply, and then disaggregated to a single cell sus-
pension. Cells derived from lungs were then loaded into
the wells of a Gardella gel that was analyzed by PCR as
above. The experiment was repeated twice with compara-
ble results. A representative selection of the results is shown
in Fig. 4. In five out of six cases, the lungs of 
 
m
 
MT mice
were found to contain both episomal and linear genomes
(
 
A
 
), but in one case, we found evidence of only episomal
genomes (
 
B
 
). In addition, all (four out of four) intact C57/
BL6 mice contained both linear and episomal forms of the
genome (
 
C
 
). After treatment of 
 
m
 
MT mice for 28 d with
4
 
9
 
-S-EtdU, we found that in all cases (four out of four),
only the episomal form of the genome was present (
 
D).
Thus, both episomal and linear forms of the MHV-68
genome were present in the majority of mouse lungs, sug-
gesting that both latently and productively infected cells
may be normally present. However, episomal DNA was
present alone in one mMT mouse, and after 49-S-EtdU
treatment (which inhibits virus DNA replication) in others.
This suggests that the persistence of MHV-68 in a latent
state in the lung may not depend on the presence of pro-
ductively infected cells.
Infectious MHV-68 Can Be Reactivated in mMT Mice.
We surmised that if MHV-68 DNA in the lungs of mice
represented intact virus, it should be possible to detect it by
biological means. All of our previous attempts to induce
the production of infectious virus from the lungs of mice
during persistent infection had failed. These included im-
munosuppression by removal of T cells, including CD41
or CD81 T cells alone as well as both CD41 and CD81 T
cells, immunosuppression with cyclosporin A, and treat-
ment with dexamethasone. Since mMT mice have no B
cells, they are unable to produce antiviral antibody. There-
fore, we attempted to obtain infectious virus from mMT
mice as well as intact C57/BL6 mice during the persistent
phase of infection, i.e., 54 d p.i. The experiment was re-
peated twice with comparable results. T cell subsets were
depleted using either anti-CD4 (YTS 191.1), anti-CD8
(YTS 169.4), or anti-CD4 and -CD8 in combination.
Control mice received PBS alone. FACSÒ analysis of lym-
phocytes after depletion revealed a .99% depletion of the
relevant T cell subset. After depletion for 14 d, the mice
were sampled, and the virus titers present in the lungs were
determined. The results are shown in Table 1. As in previ-
ous experiments, MHV-68 could not be reactivated from
intact mice. However, infectious virus was recovered from
mMT mice after depletion of either CD81 T cells or CD41
plus CD81 cells. The amount of virus recovered was small
in the case of CD81 T cell depletion, but was much
greater, approaching levels seen during acute infection, in
CD41 plus CD81–depleted animals.
We have found no other site of persisting MHV-68 than
the lungs in mMT mice infected by the intranasal route.
Therefore, the above results suggest that the persisting virus
detected by molecular methods in lungs may not be defec-
tive, and is capable of replicating to high levels in the ab-
sence of both antiviral antibody and T cells.
Latent MHV-68 Persists in Lung Epithelial Cells. To de-
termine the cell type harboring MHV-68 in the lung dur-
Figure 4. Analysis of MHV-68 DNA conformation in lung cells by
Gardella gel–PCR analysis. Intact cells were loaded into the wells of a
Gardella (in situ–lysis) gel. After electrophoresis, individual lanes were cut
sequentially into slices. Slices from each lane were then analyzed by PCR
for the presence of MHV-68 DNA. PCR products were analyzed on 2%
agarose gels containing ethidium bromide and visualized using a UV trans-
illuminator. Images are shown with the colors reversed for clarity. There-
fore, each panel represents one lane of a Gardella gel, and the top is
shown next to the first of the sequential slices. The slices representing the
positions on the Gardella gel of the circular and the linear forms of the
genome are shown (top). In all panels, DNA from the MHV-68–positive
tumor cell line S11 was used as a positive control (1), and produced the
expected product of 368 bp. DNA from the MHV-68–negative tumor
cell line S31 (2) was used along with deionized water (H2O) as a negative
control. A, B, and D show results using cells from mMT mouse lungs
2 mo p.i., whereas C shows results using cells from C57/BL6 mice lungs
7 mo p.i. and are labeled accordingly. D shows the results using mMT
mouse lungs at 2 mo p.i., but after treatment for the last 28 d of infection
with the inhibitor of virus DNA replication 49-S-EtdU.
Table 1. Induction of Infectious MHV-68 from the Lungs of 
Persistently Infected Mice by Immunosuppression
Treatment
Virus titer in
C57/BL6 lungs*
Virus titer in
mMT lungs*
PFU/lung PFU/lung
PBS ,10 ,10
anti-CD4 ,10 ,10
anti-CD8 ,10 15
anti-CD4 1 CD8 ,10 6 3 105
*Titers are expressed as the mean of three individual mice.1946 Gammaherpesvirus Latency in Epithelia1947 Stewart et al.
ing persistence, we performed in situ hybridization on tis-
sue sections taken from either mMT (n 5 3) or C57/BL6
(n 5 3) mice during the persistent phase at 54 d p.i. Con-
trol hybridizations were performed on sections from mock-
infected mMT and C57/BL6 mice. Sections were hybrid-
ized initially with a 35S-labeled riboprobe complementary
(antisense) to the MHV-68 tRNA-like genes that are ex-
pressed during MHV-68 latency (19). As controls, adjacent
serial sections were hybridized with a sense tRNA probe
and a probe that hybridized to mRNAs encoding the
MHV-68 thymidine kinase and gH proteins which are ex-
pressed during the productive phase of MHV-68 infection
(24). Representative examples of the results are shown in
Fig. 5.
No reaction was seen using the control sense tRNA
probe or antisense tRNA probe on sections from mock-
infected mice (not shown). Foci of positive cells were ob-
served in sections from all six infected mice, either mMT or
C57/BL6, using the antisense tRNA probe (Fig. 5, A and
C). These foci were small, and there were between one
and five (mean two) per section. There was no reaction us-
ing the thymidine kinase plus gH probe on adjacent serial
sections (B); however, control hybridizations showed that
the thymidine kinase plus gH probe was capable of detect-
ing productively infected cells present during acute infection
(H). Therefore, it seems likely that the tRNA-expressing
foci observed were cells latently infected with MHV-68.
Further, the position of the foci within the biopsy sug-
gested that these latently infected cells were not centered
on areas of inflammation or blood vessels, but were border-
ing airways and were possibly epithelial cells.
To identify precisely the cell type involved, we per-
formed a second set of in situ hybridizations using a digox-
igenin-labeled antisense tRNA probe. The same sections
were reacted with an mAb specific for cytokeratin. Positive
control sections taken from the acute phase of infection
were used for comparison. During the productive phase of
infection, MHV-68 tRNAs (dark blue) were expressed in
the nuclei of a large number of cells, which also expressed
cytokeratin (brown) and were thus epithelial (G). As can be
seen in Fig. 5 D–F, during latency only small foci of cells
positive for tRNA sequences were present; however, these
cells were also positive for cytokeratin. Thus, the lung cells
that expressed MHV-68 tRNAs during the persistent phase
of infection were epithelial in nature.
Movement of MHV-68 between Lung and Spleen during Vi-
rus Latency. Our data showed that lungs and spleen were
sites of MHV-68 latency and persistence. We wished to
know whether these sites were truly independent, or
Figure 5. Determination of cell type harboring latent MHV-68 in the lungs by in situ hybridization. Sections of 5 mM thickness were cut from forma-
lin-fixed paraffin-embedded lung tissues from mice during virus persistence at 54 d p.i. (A–F). Control sections were derived from mice at 5 d p.i. (G and
H, acute). Sections shown in A–C and H were hybridized with 35S-labeled riboprobes and developed using photographic emulsion. The sections shown
in D–G were hybridized with digoxigenin-labeled riboprobes and developed using a combination of alkaline phosphatase–labeled antidigoxigenin fol-
lowed by NBT/BCIP (blue/black). Probes used were specific for either the latency-associated tRNAs (A and C–G, tRNA) or the productive cycle–asso-
ciated thymidine kinase (TK) and gH genes (B and H, TK 1 gH). D–G were additionally reacted with anticytokeratin antibody and developed using
DAB (brown, anti-CK). A and B are adjacent serial sections from one mMT mouse biopsy. All other panels are derived from different mMT mice. A–C
and H were counterstained with hematoxylin and eosin. A and B, 3230; C–H, 3580.
whether virus resident in the spleen was able to traffic to
the lung and virus resident in the lung was able to spread to
the spleen.
To see whether MHV-68 persisting in spleens of mice
could spread to the lungs, we took T-depleted cells from
the spleens of C57/BL6 mice that had been either mock-
infected or infected with MHV-68. We then infused these
cells into uninfected mMT mice. The mice were tested
pretransfer and found to have no B2201 cells in the blood.
When tested 4 d after transfer, they were found to have be-
tween 1 and 18% B2201 cells, indicating that adoptively
transferred cells were persisting. After 11 d, the spleens,
lungs, and blood of these mice were screened for the pres-
ence of MHV-68 by PCR. Before removal, the lungs were
perfused with PBS to remove contaminating lymphocytes
present in the blood supply. The results are shown in Fig. 6
A. None of the mice that received B cells from uninfected
mice (Mock) had evidence of MHV-68 infection. Two out
of five mice that received cells from infected mice had evi-
dence of infection in both the spleen and the lungs but not
the blood. Thus, in the mice where transfer had been suc-
cessful in establishing infected B cells in the spleen, there
was also evidence of infection in the lung. This implies that
virus resident in splenic B cells is able to spread and estab-
lish infection in the lungs.
To see whether persisting MHV-68 resident in the lungs
of mice could spread to the spleen, we exploited the fact
that MHV-68 persists in the lungs of mMT mice in the ab-
sence of any evidence of splenic infection. Therefore, we
took mMT mice that had been mock-infected or infected
with MHV-68 for 80 d. We then infused T-depleted sple-
nocytes from C57/BL6 mice into these mice. The mice
were tested pretransfer and found to have no B2201 cells in
the blood stream. At 2 d after transfer, they had between 1
and 18% B2201 cells in the blood stream, indicating that
adoptively transferred cells were persisting. After 14 d, the
mice were sampled, and the lungs and spleen were tested
for the presence of MHV-68 by PCR. Again, before removal,
the lungs were perfused to remove contaminating B cells in
the blood volume. The results are shown in Fig. 6, B and
C. B shows in a control experiment that virus was present
in the lung but not the spleen of persistently infected mMT
mice. This supports our previous observations (13). C shows
the results of transfer experiments into similar mice. No vi-
rus was evident in either the lungs or spleen of two mock-
infected mice. However, MHV-68 infection was seen in
both the lungs and the spleen of infected mice. Therefore,
this shows that in the presence of B cells, MHV-68 persist-
ing in the lungs can establish infection in the spleen.1948 Gammaherpesvirus Latency in Epithelia
Discussion
The above data showed that MHV-68 could persist in
the lungs of both intact and B cell–deficient mice. Both ep-
isomal and linear forms of the genome were detected by
Gardella gel analysis in lungs, implying the presence of la-
tency and productive replication, and we have shown that
persisting virus can be recovered in infectious form after
immunosuppression. Latent MHV-68 was seen in pulmo-
nary epithelial cells during persistent infection, but produc-
tively infected cells were not found. Adoptive transfer ex-
periments suggested that virus persisting in the lungs could
seed the spleen, and conversely, virus resident in the spleen
could seed the lungs.
We have used the mMT B cell–deficient mouse since we
and others have shown that MHV-68 persists in the lungs
but not in the spleen or any other organ yet detected after
intranasal infection of these mice (13, 25). Other workers
have shown that the virus is able to infect and persist in the
spleen of mMT mice, but only after intraperitoneal inocu-
lation of a larger dose of virus, which enables a more dis-
seminated, systemic infection to be established (26). This
implies that B lymphocytes are required for MHV-68 to
traffic and seed the spleen after respiratory challenge, and
that in the absence of B cells, alternative cell types within
the spleen are capable of harboring persisting virus. Our
data using intranasal infection do not conclusively exclude
the possibility of a more complicated host–pathogen rela-
tionship, such as the one that exists with CMV, where
multiple sites have an important input into persistence.
However, in mMT mice, we have never detected virus
DNA in any organ other than the lung during persistence.
This and the absence of virus DNA in the blood of mMT
mice (Fig. 6 A) strongly suggest that the lung may be the
primary source of persistence in the current experiments.
Therefore, we believe that intranasal infection of mMT
mice provides a powerful means of studying persistence of
a gammaherpesvirus at a mucosal site. Data obtained with
the mMT strain are likely representative, because the pat-
terns of persistence in the lungs of these mice are mirrored
in all aspects by intact C57/BL6 mice.
Molecular analysis suggested that the mode of MHV-68
persistence was a mixture of latency and productive repli-
cation in both mMT and intact mice. Evidence of virus
persistence in the lungs has never been obtained using bio-
logical criteria such as direct plaque or reactivation assays.
However, our data (Table 1) showed that infectious virus
could be recovered in the lungs of mMT mice after T cell
depletion. We have not found virus in any other organ in
this system, although this does not exclude the presence of
small amounts of latent virus in some hitherto unrecog-
nized site. Also, one issue that cannot be resolved conclu-
sively here is whether the infectious virus detected was due
to the amplification of small amounts of persistent active
replication present in the mMT mice because of immuno-
deficiency or reactivation of latency. Even so, our data
strongly suggest that the infectious virus found in the lungs
originates there, and that the virus found by molecular
means is not defective. Previous failure to detect MHV-68
in lungs by biological methods is unlikely to be due to
the level of virus being below the level of detection, since
the lungs contained a comparable amount of virus DNA to the
Figure 6. Detection of MHV-68 in organs of mMT mice after adoptive transfer of B lymphocytes. MHV-68 genomes were detected by nested PCR
for gp150. Products were analyzed on 2% agarose gels containing ethidium bromide and visualized using a UV transilluminator. Images are shown with
the colors reversed for clarity. Molecular weight determinations were made relative to a 1-kb DNA ladder (Mr), and the size of the pertinent bands in bp
are shown at the left. In all panels, DNA from the MHV-68–positive tumor cell line S11 was used as a positive control (1VE), and produced the ex-
pected product of 368 bp. DNA from the MHV-68–negative tumor cell line S31 (2VE) was used along with deionized water (H2O) as a negative con-
trol. (A) T-depleted splenocytes from infected (INF 1–4) or mock-infected (MOCK 1–3) C57/BL6 mice were adoptively transferred into uninfected
mMT mice. After 11 d, DNA was extracted and analyzed for MHV-68 by nested PCR. Results from analysis of the spleens, lungs, and blood are indicated
above the relevant tracks. (B) Three persistently infected mMT mice (1–3) were analyzed for MHV-68 by nested PCR. Results from either lungs or spleen are
shown above the relevant tracks. (C) T cell–depleted splenocytes from uninfected C57/BL6 mice were adoptively transferred into either mock-infected
(MOCK 1 and 2) or persistently infected (INF 1–3) mMT mice. After 14 d, DNA was extracted and analyzed for MHV-68 by nested PCR. Results from
analysis of the spleens and lungs are indicated above the relevant tracks.1949 Stewart et al.
spleens (see Fig. 2). A more likely explanation is that epi-
thelial cells in which the virus resides may be less able to
support in vitro reactivation than B lymphocytes in the
spleen.
The precise mechanisms governing the control of reacti-
vation of gammaherpesviruses in the host are not known.
Certainly, T cells play a critical role, since humans who are
either iatrogenically depleted of T cells or deficient in T cell
function because of disease can succumb to EBV-driven
lymphoproliferative disease (27). In addition, AIDS patients
often develop Kaposi’s sarcoma which is KSHV-associated
(2). However, our results have shown that depletion of T
cells alone did not result in the reactivation of MHV-68.
Reactivation was achieved in mMT mice in the absence of
both antibody and T cells. Although additional experi-
ments are required to confirm this, these results strongly
suggest a role for antibody in the control of gammaherpes-
viruses after reactivation. Thus, the presence of antiviral an-
tibody in intact mice presumably prevented the spread of
reactivated virus even in the face of severe immunosup-
pression. This may explain in part why EBV-driven lym-
phoproliferative disease often only develops after many
months of T cell depletion (27). A long time may be re-
quired in the absence of T cells for B cell memory and an-
tibody to decline to a level that is sufficient for virus reacti-
vation to occur. Such a role for antibody is not unique.
Elegant work, also using the mMT strain of mice, has
shown that antiviral antibodies are important for the con-
trol of recurrent murine CMV (28).
Detection of the productive form of MHV-68 in lungs
during persistence is perhaps not surprising, since this is the
target organ for productive replication during acute infec-
tion, and productive replication at a mucosal site also pro-
vides a means for the virus to spread from host to host.
Also, a similar pattern of low-level, sporadic productive
replication at mucosal sites is seen during persistence of
EBV (1). However, the numbers of cells undergoing pro-
ductive MHV-68 replication in the lung at any one time
must be small, since although we detected them by
Gardella gel analysis, they were not seen by in situ hybrid-
ization or immunohistochemistry.
Detection of murine gammaherpesvirus in epithelial cells
at a mucosal surface in an episomal conformation and in the
absence of lytic cycle gene expression suggests that at least
some of the epithelial cells at this site were latently infected.
As such, this is a novel and important finding. The impact
of this is increased by the observations that in mMT mice,
lungs are the only known organ of persistence, and treat-
ment with a herpesvirus DNA replication inhibitor for 28 d
did not affect persistence at this site. This strongly suggests
that the persistence of a latent MHV-68 infection in the
lungs did not absolutely require constant reseeding from
other sites such as the lymphoid compartment or local pro-
ductive replication. However, our results do not preclude
that reseeding of this site from other organs does not occur
during persistence in intact mice. This may have implica-
tions for our view of the pathogenesis of other gammaher-
pesviruses. Persistence at mucosa has been addressed only
with one other gammaherpesvirus, EBV. Epithelial cells
containing productively replicating EBV and derived from
an unknown source can be found in saliva (5). However,
latently infected cells have never been seen in mucosal bi-
opsies, and long-term treatment of patients with Acyclovir
results in the loss of EBV from the mucosa but not the
blood (6, 10). Therefore, it has been suggested that mucosa
are not essential for EBV persistence in a given host, and
that constant reseeding from the lymphoid compartment is
required to maintain a virus presence at these sites. Experi-
ments in humans and large animals are hard because of eth-
ical considerations and the difficulty in obtaining biopsy
material. In addition, our data suggest that the amount of
gammaherpesvirus at mucosal sites is likely to be low.
Therefore, it is possible that virus persisting at mucosal sur-
faces in other systems may have been missed. An alternative
explanation is that the ability to persist at a mucosal site or
not might represent a fundamental biological difference be-
tween different members of this subfamily. However, this
question cannot be resolved until the persistence of EBV,
KSHV, and other gammaherpesviruses is reevaluated to in-
clude alternative sites of mucosal persistence, such as the
lung. This may turn out to be particularly pertinent be-
cause of the association of persistent gammaherpesvirus in-
fection with diseases of mucosa. These include the associa-
tion of EBV with nasopharyngeal carcinoma (1), oral hairy
leukoplakia (4), and idiopathic pulmonary fibrosis (29) and
the association of KSHV with sarcoidosis (30).
Work with EBV has suggested that latency in B cells is
central to the maintenance of persistence, and that virus can
traffic from these cells and seed mucosa. Certainly, our re-
sults shown in Fig. 2 suggest that virus resident in the lym-
phoid compartment plays a central role in the persistence of
MHV-68 in intact mice. Our data using uninfected mMT
mice which had infected splenocytes transferred into them
(Fig. 6 A) suggest that, like EBV, virus may be able to traf-
fic from B cell to mucosa during MHV-68 persistence.
However, transfer of naive B cells into infected mMT mice
where mucosa may be the only site of persistence suggested
that in addition, MHV-68 are able to traffic to seed B cells.
Therefore, these results suggest that epithelial cells in mu-
cosa may be as important as B cells during MHV-68 persis-
tence, and that there may be a dynamic, two-way move-
ment of virus between the lymphoid and nonlymphoid
reservoirs. This may form part of the survival strategy of the
virus. Thus, persistence and replication may be required at
a mucosal site in order to ensure transmission to new hosts.
An additional reservoir of latent virus in lymphoid tissue
with a limited flow of virus between the two sites may en-
sure that the virus is never cleared from either site.
Work is now under way to ascertain the nature of the la-
tent state in the lung of infected mice. A key issue is
whether the pattern of latent gene expression seen in the
B cell is reflected in lung epithelial cells. The consequences
of long-term infection of the lung with MHV-68 provides
a unique opportunity to explore links between gammaher-
pesvirus infection and lung diseases of man and animals of
unknown etiology.1950 Gammaherpesvirus Latency in Epithelia
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